Zealand Pharma A/S (ZLDPF)
51.80
+3.56
(+7.39%)
USD |
OTCM |
Aug 25, 16:00
Zealand Pharma Net Income (Quarterly) : 609.41M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 609.41M |
| March 31, 2026 | -61.70M |
| December 31, 2025 | -59.08M |
| September 30, 2025 | -63.29M |
| June 30, 2025 | 1.150B |
| March 31, 2025 | -47.31M |
| December 31, 2024 | -41.62M |
| September 30, 2024 | -39.23M |
| June 30, 2024 | -42.25M |
| March 31, 2024 | -33.28M |
| December 31, 2023 | -38.18M |
| September 30, 2023 | 10.82M |
| June 30, 2023 | -46.68M |
| March 31, 2023 | -27.91M |
| December 31, 2022 | -44.03M |
| September 30, 2022 | -20.55M |
| June 30, 2022 | -56.96M |
| March 31, 2022 | -14.33M |
| December 31, 2021 | -32.39M |
| September 30, 2021 | -22.42M |
| June 30, 2021 | -48.18M |
| March 31, 2021 | -39.23M |
| December 31, 2020 | -60.95M |
| September 30, 2020 | -35.89M |
| June 30, 2020 | -8.591M |
| Date | Value |
|---|---|
| March 31, 2020 | -26.47M |
| December 31, 2019 | -28.70M |
| September 30, 2019 | -16.87M |
| June 30, 2019 | -20.64M |
| March 31, 2019 | -19.40M |
| December 31, 2018 | -18.80M |
| September 30, 2018 | 143.43M |
| June 30, 2018 | -17.64M |
| March 31, 2018 | -16.07M |
| December 31, 2017 | -17.51M |
| September 30, 2017 | -6.804M |
| June 30, 2017 | -13.96M |
| March 31, 2017 | -3.774M |
| December 31, 2016 | 7.640M |
| September 30, 2016 | -4.634M |
| June 30, 2016 | -14.87M |
| March 31, 2016 | -11.50M |
| December 31, 2015 | 10.23M |
| September 30, 2015 | -7.645M |
| June 30, 2015 | -11.39M |
| March 31, 2015 | -8.382M |
| December 31, 2014 | -10.57M |
| September 30, 2014 | 2.998M |
| June 30, 2014 | -8.772M |
| March 31, 2014 | 5.297M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Genmab A/S | 302.57M |
| Ascendis Pharma A/S | 240.65M |
| Bavarian Nordic A/S | 113.83M |
| Evaxion AS | -3.724M |
| Novo Nordisk A/S | 3.265B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 698.72M |
| Total Expenses (Quarterly) | 89.30M |
| EPS Diluted (Quarterly) | 8.610 |
| Enterprise Value | 1.468B |
| Gross Profit Margin (Quarterly) | 99.76% |
| Profit Margin (Quarterly) | 87.22% |
| Earnings Yield | 11.58% |
| Operating Earnings Yield | 9.96% |
| Normalized Earnings Yield | 11.67 |